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Abstract
Rhinosinusitis is a common disease among all the sinus diseases, and unsuccessful attempts 
to these infections may result not only in economic burdens but also in increasing the num-
bers of untreated patients in the community. Medical management of the rhinosinusitis 
includes antibiotics, antihistamines, nasal decongestants, corticosteroids, mucolytics, 
leukotriene antagonists, and nasal irrigations. Each treatment option must be selected for 
appropriate patient and prescriptions must be tailored according to the patient’s need. 
These needs must depend on the endoscopic examination, symptoms, and sinus cultures 
and computed tomography. It is also a matter of debate whether these investigations lead 
to treatment or not, but it would be wrong to expect that a single examination method and 
physical examination alone should direct treatment in the first place. As a result, managing 
the process with the most appropriate examination methods for the patient’s complaints 
will be the most beneficial approach.
Keywords: acute rhinosinusitis, chronic rhinosinusitis, pediatric, adult, nasal polyp, 
antibiotic
1. Introduction
Rhinosinusitis is the major public health problem among the upper respiratory tract infec-
tions that produce enormous consequences that source the negative effect on the quality of 
life of the patient and cause significant morbidity and mortality. Rhinosinusitis also has a 
significant effect on the health economics. In the United States, the predicted yearly amount 
of the burden has been estimated at $3.5–5.8 billion, especially $1.8 billion for first 12 years of 
age [1]. It seems that rhinosinusitis affect the quality of life of the children and cause economic 
loss. It is imperative to obtain up-to-date and accurate information for each physician who 
is involved in the treatment of this disease group and related ones. In this chapter, updated 
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information has been given about the medical treatments on pediatric acute rhinosinusitis, 
pediatric chronic sinusitis, adult acute rhinosinusitis, adult chronic rhinosinusitis without 
nasal polyp (CRSsNP), and adult chronic rhinosinusitis with nasal polyp (CRSwNP). This 
information has been compiled from very important guidelines and articles by authors. In this 
way, the reader will be able to acquire much more detailed and accurate information as well 
as the source of the information to be obtained.
2. Medical management of pediatric acute rhinosinusitis
2.1. Oral antibiotics
Oral antibiotic treatment is not necessitating the majority of the acute rhinosinusitis (ARS) 
patients. Viral infections that resolve without therapy are the main cause of rhinosinusitis [2]. 
A minor proportion of these patients develop a subsequent bacterial inflammation that will 
heal with antimicrobial treatment. Streptococcus pneumoniae, Haemophilus influenzae, Moraxella 
catarrhalis, Group A beta-hemolytic streptococci, and Staphylococcus aureus are the most com-
mon cause of the development of rhinosinusitis. Therefore, the patient who has taken oral 
antibiotic therapy is the most important concern in clinical practice. However, acute rhinosi-
nusitis with viral etiology may be resolved without any treatment but bacterial rhinosinusitis 
is treated by antibiotics. The diagnosis of bacterial ARS may be considered when symptoms 
prolonged over 10 days or there is deterioration after drug-free follow-up period [3]. The 
guideline from the American Academy of Pediatrics [4] suggested that physicians must use 
antibiotic treatment for ARS in children with intense beginning or deteriorating progression. 
As well, reporters also advised that physicians should either use antibiotic therapy or offer 
further outpatient observation for 3 days to children with persistent disorder. This report 
also confirmed that if there is no improving in symptoms or if there is a failure to recover, 
clinicians should modify antibiotics or initiate antibiotics in child treated with observation [4]. 
The recommendation of using antibiotics for severe or worsening acute bacterial sinusitis in 
consequence of the benefits showed a theoretically higher risk of suppurative complications 
than for children who existed lasting symptoms.
It is recommended that when the clinical diagnosis of acute bacterial rhinosinusitis (ABRS) 
is established, empirical antimicrobial therapy should be initiated directly [5]. Amoxicillin-
clavulanate (45 mg/kg/day, divided into two doses) instead of amoxicillin alone is recom-
mended as the initial therapy of ABRS in children. The cephalosporins such as cefuroxime, 
cefdinir or cefpodoxime, clindamycin (or linezolid) + cefixime, and levofloxacin may be pre-
ferred in the condition of a penicilin allergy. Cephalosporins are usually used as the suitable 
treatment for ARS. Cephalexin and cefadroxil, which are the first-generation agents, are not 
the first choice for H. influenzae infection. Beta-lactamase-producing M. catarrhalis and some 
H. influenzae strains has reduce the response to cefaclor (50 mg/kg/day in two doses), and 
early second-generation cephalosporins. On the other hand, beta-lactamase-producing bac-
teria have a good response to second-generation cephalosporins (cefuroxime axetil, 30 mg/
kg/day and cefprozil, in two doses as oral suspension). Third-generation cephalosporins such 
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as cefixime, ceftibuten, cefpodoxime axetil (10 mg/kg once daily), and cefdinir (14 mg/kg/
day in one or two doses) seem to be an alternative option for the therapy. Macrolides (clar-
ithromycin and azithromycin) are not recommended for empirical treatment due to elevated 
resistance rates of S. pneumoniae. Because of high resistance rates between S. pneumoniae and 
Haemophilus influenzae, trimethoprim-sulfamethoxazole is not recommended for empiri-
cal treatment. Ampicillin-sulbactam (100 mg/kg/day for three times a day) or ceftriaxone 
(100 mg/kg/day at single or double dose) given intravenously or intramusculary can be used 
in patients who do not endure oral antibiotics due to vomiting or in patients who do not 
recover after 24–48 hours of treatment with a second antibiotic therapy. If there is a suspicion 
of an aerobic pathogen as a cause of ARS, clindamycin or metronidazole may be added to 
a wide spectrum antibiotics. In patients with acute bacterial RS, the appropriate treatment 
duration is not definitively defined, but 10–14 days of treatment appear to be adequate for 
mild acute forms, but 14–21 days of treatment appear to be appropriate for severe acute forms 
and subacute forms [5].
2.2. Intranasal saline irrigation
Nasal saline irrigation has been shown to be effective and well tolerated in children with 
rhinosinusitis [6]. Management of sinus disease often involves the use of saline irrigations. 
Saline irrigation helps patients with rhinosinusitis by improving mucociliary clearance, 
slenderizing mucus, and providing anti-inflammatory effects [7]. Decreasing in symptoms 
after nasal irrigations is associated with an increase in quality of life in patients with acute 
rhinosinusitis [3, 8, 9].
2.3. Intranasal corticosteroids
It has been also shown that the use of intranasal corticosteroids significantly improved the 
symptoms of ARS [3]. Intranasal corticosteroids are recommended for both moderate (mono-
therapy) and severe (oral antibiotics) types of acute rhinosinusitis [10]. A double-blind, 
placebo-controlled trial revealed the efficacy of topical corticosteroid therapy in comparison 
with both monotherapy and antibiotics [11]. In this study, mometasone furoate (MF) was 
compared with amoxicillin and placebo in patients with ARS. MF 200 μg twice a day was sig-
nificantly better than placebo and amoxicillin for correction of symptom score. MF was used 
once a day and was superior to placebo but not to amoxicillin. This study is the first study 
to show that topical corticosteroids are effective when given twice daily in the treatment of 
ARS and are more effective than amoxicillin. The results of this study were also supported 
by two other studies with a similar design. However, in another study, the use of antibiotics 
and topical steroids alone and in combination has not been effective in changing the severity 
of symptoms or duration of bacterial ARS. However, in this study, the patients with 4 days 
of symptoms and only those with colds and not ARS have been included. It is supported by 
the use of intranasal corticosteroids alone or as adjuvant therapy to antibiotics. High doses 
of intranasal corticosteroids (mometasone furoate 400 versus 200 μg) have a stronger effect 
on the reduction or complete improvement of symptoms. There was no significant adverse 
effect for both treatment groups, and there was no significant difference in the reduction in 
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symptoms and recurrence rates with higher doses of intranasal corticosteroids. Further ran-
domized clinical trials are needed to examine the effectiveness and proper use of antibiotics 
and intranasal corticosteroids as a single or combined therapy for the treatment of differ-
ent severe ARS. There are some studies comparing the effectiveness of mometasone furoate 
nasal spray and amoxicillin and placebo in patients with acute, uncomplicated RS. It is con-
cluded that the use of mometasone furoate twice daily as 200 μg in acute, uncomplicated 
RS patients significantly reduced symptoms when compared with amoxicillin and placebo 
without predisposing factors or bacterial infection [12]. Rahmati et al. [13] revealed that the 
use of fluticasone in children has been associated with reducing the severity of acute sinusitis 
symptoms. Foden et al. [7] stated that intranasal corticosteroids (INCS) are the basis for the 
treatment of rhinosinusitis. As a monotherapy in ARS, INCS had a significant improvement 
in symptoms compared to placebo and amoxicillin [12]. On regarding the use of INCS, either 
as monotherapy or adjuvant to antibiotics, these studies have also been designed based on the 
approval of diagnosis. Intranasal corticosteroids (INCSs) are recommended in patients with 
a history of allergic rhinitis, especially as an adjunct to antibiotics for the empirical treatment 
of ABRS [5].
2.4. Other treatment modalities
It was accepted as a symptomatic treatment of viral upper respiratory tract infections with 
analgesic, antipyretic, and decongestant drugs (topical or systemic) [6]. Decongestants 
should be used with caution in pediatric patients because there is a small number of studies 
on the efficacy and side effects of decongestants. Concurrent use of decongestant and anti-
histamine in the treatment of pediatric upper respiratory tract infection and inflammation 
is still debated. In patients with ABRS, topical or oral decongestants and/or antihistamines 
are not recommended as adjuvant therapy (strong, low to moderate). Oral corticosteroids 
may be added to the treatment of cases with nasal polyposis or marked mucosal edema 
when the initial treatment is not received [14]. Antihistamines are useful in the case of 
accompanying acute bacterial RS and allergic RS because they reduce the inflammatory 
component and respond positively to antibiotics. Except the current allergic rhinitis, there 
is no indication for the use of antihistamines (both intranasal and oral) in the treatment of 
postviral ARS [10].
2.5. Nonresponsive patients
The patients who have worsened clinically during the first 72 hours or who have not recovered 
after 3–5 days of empirical antimicrobial therapy with a first-step agent should be evaluated 
for resistance pathogens, nontoxic etiology, structural abnormality, or other reasons for treat-
ment failure (strong, low). In patients with suspected sinus infection who cannot respond to 
empirical antimicrobial therapy, cultures are recommended to be obtained with direct sinus 
aspiration rather than nasopharyngeal swab (strong, moderate). Endoscopic-guided cultures 
of medium meatus may be considered as an alternative in adults, but their reliability was not 
determined in children (weak, moderate). Nasopharynx cultures are not considered reliable 
and are not recommended for microbiological diagnosis of ABRS [5].
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3. Medical management of pediatric chronic rhinosinusitis
3.1. Intranasal saline irrigation
Nasal saline irrigation should be considered as the primary therapeutic tool in CRS, even in 
the child age group, which is a long-term CRS [15–17]. Nasal saline lavage can significantly 
reduce chronic sinusitis symptoms, improve disease-specific quality of life, and be well toler-
ated in children with chronic rhinosinusitis symptoms [6, 18]. Nasal saline solutions make it 
easier to mechanically remove the mucus and increase the ciliary rhythm [19]. Nasal saline 
sprays or irrigations when tolerated are also used in the treatment of CRS, and primarily, 
sinonasal secretion, pathogens and debris removal are thought to help. Although Cochrane 
collection does not support any advice on nasal saline irritation, some studies have shown 
some degree of efficacy in CRS [16].
3.2. Intranasal corticosteroids
Topical steroids, although the absolute resolution of the CRS does not improve, may accelerate 
the solution of CRS symptoms when evaluated in the short term. In the management of CRS, 
it may be affected by suspected or proven allergic disease, including steroids. In particular, 
nasal steroids should be maintained when an allergic patient is treated for CRS. Topical nasal 
steroids suppress mucosal inflammation [9]. Examples include fluticasone propionate, com-
monly found in generic form, and mometasone furoate, which is indicated for use in nasal 
congestion due to allergic rhinitis in children aged 2 years and older. Topical nasal steroids 
are usually preferred for children with CRS due to low systemic bioavailability. Therefore, 
systemic side effects are rare in children with CRS and the most common complication is 
epistaxis. Although long-term prophylactic use often seems to be safe, it helps to suppress 
chronic symptoms and recurrent diseases, and typically conflicts with long-term antibiotic 
medicines used in CRS every 3–6 weeks [16].
3.3. Antibiotic treatment in the management of pediatric chronic rhinosinusitis
3.3.1. Oral antibiotics
Long-term and broad-spectrum antibiotics have been the basis for treating pediatric chronic 
rhinosinusitis. Amoxicillin/clavulanate is a good choice for first-line treatment, but antibiotics 
to be selected must also be effective against possible pathogens in CRS, including S aureus, 
Pseudomonas and anaerobes. Encompassing for MRSA may be indicated. Long-period 
treatment with macrolides for up to 12 weeks may also benefit patients with CRS. A culture 
should be obtained, preferably directly from the sinus cavity or endoscopic, in patients who 
do not recover or develop worsening despite treatment. For the last 20 years, antimicrobial 
resistance has been increasing. These contain the creation of beta lactamases and cephalo-
sporins. Clindamycin can be administered in the event of penicillin allergy or who suspect 
MRSA. Other oral agents covering MRSA include trimethoprim-sulfamethoxazole and line-
zolid. The dose of amoxicillin-clavulanate recommended for children is 45 mg/kg. Another 
Medical Management of the Paranasal Sinus Infections
http://dx.doi.org/10.5772/intechopen.81040
61
recommended antibiotic management procedure is high-dose amoxicillin or amoxicillin/
clavulanate (90 mg/kg/day orally twice daily) for children from environmental areas with 
high endemic degrees (>10%) of aggressive penicillin-nonsusceptible (PNS) S. pneumoniae. In 
addition, high-dose amoxicillin or amoxicillin/clavulanate therapy is recommended for the 
children with severe infection, attendance at nursery, age<2, latest hospitalization, antibiotic 
usage within the past month, and immunocompromisation [6, 16, 20]. Metronidazole can be 
administered in addition to one of the following antibiotics: cefazolin, cefuroxime, cefixime 
proksetil, clarithromycin, azithromycin, or trimethoprim-sulfamethoxazole and  is adminis-
tered as three times a day for 30–50 mg/kg/day and maximum daily dose for 2.250 mg/day. 
Antimicrobial therapy is given for a three-week period and can be extended up to 10 weeks in 
patients with antibiotic resistance [19].
3.3.2. Parenteral antibiotics
Parenteral treatment is applied to children who are extremely ill, who undergo surgery or 
who have a problem of adaptation to the oral regimen. Among the parenteral antimicrobi-
als such as ampicillin-sulbactam, piperacillin-tazobactam, clindamycin, moxifloxacin, car-
bapenems (imipenem, meropenem, doripenem), and second-generation cephalosporins, 
cefoxitin effective against both anaerobes and aerobes are included. Vancomycin, linezolid, 
and daptomycin and ceftaroline are among the parenteral antimicrobials effective against 
MRSA. Metronidazole may be given as parenteral against anaerobes in combination with an 
agent with aerobic activity [9, 20].
3.3.3. Intranasal antibiotics
Although topical antibiotic treatment is not recommended in the best part of CRS cases, fur-
ther studies should be required according to the initial findings. Demands about the combina-
tion potential with dose, treatment time, optimal treatment method, and other therapies carry 
on to be responded [9].
3.4. Systemic corticosteroids
Oral methylprednisolone has a good tolerance and offers additional benefit to treatment 
with antibiotics for children with CRS [21]. Combination treatment with systemic corti-
costeroids and antibiotics was established to be favorable in children (age between 6 and 
17 years) with CRS whose management with at least three 10–14–day sequences of wide-
spectrum antibiotics was unsuccessful. Minimal side effects may be seen. It was observed 
that children treated with corticosteroids plus antibiotics had meaningfully better declines 
in entire symptom and sinus CT scores compared with those given placebo plus antibiotics. 
Complete clinical healing observed more frequently and reverts within 6 months less com-
monly in the active management group. Moreover, Ozturk et al. [21] conducted a random-
ized trial comparing amoxicillin-clavulanate with and without methylprednisolone, and 
examined the advantage of addition of systemic corticosteroids to oral antibiotics for the 
management of CRS. Both management arms revealed progress compared with baseline 
with the steroid management being meaningfully more effective regarding dropping CT 
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scores and total rhinosinusitis symptoms, such as nasal obstruction, cough, and postnasal 
drainage [22].
3.5. Adjuvant medical treatments
Adjuvant medical treatment involving antihistamines and decongestants for pediatric CRS 
has been used widely with unconfirmed benefits. Oral antihistamines and decongestants 
may offer symptomatic advance; but the general period of the disease may not be affected. 
Moreover, the effects of antihistamines and decongestants on secretions and mucosa may 
undesirably affect the innate physiologic mechanisms of the sinuses and nose to cope with 
infection and inflammation [9, 16, 19].
3.6. Treatment for gastroesophageal reflux
It is not proved to use proton pump inhibitors (PPI) for pediatric CRS. The International 
Consensus Statement on Allergy and Rhinology: rhinosinusitis [23] summaries the facts 
about CRS and laryngopharyngeal reflux. It has set grade B evidence to prove the relation-
ship between these situations but expresses that treatment guidelines or mechanistic trials are 
requiring. This statement further endorses to establish accurately diagnosing laryngopharyn-
geal reflux before starting PPI management in patients with difficult to treat CRS [24].
4. Medical management of adult acute rhinosinusitis
4.1. Nasal saline spray/saline irrigation
In the treatment of adult ABRS, there has been a recommendation of topical nasal saline irri-
gation with either isotonic or hypertonic form as a combined treatment. Saline sprays have 
an effect on reducing rhinitis symptoms. Also, it revealed a better sinus-related quality of life, 
decreased symptoms, and drug use with routine hypertonic nasal saline irrigation. No seri-
ous side effect has been determined with saline irrigation. When compared to isotonic saline, 
hypertonic saline treatment may have a better anti-inflammatory result and ability to subtilize 
mucous and rapidly recover mucociliary clearance [5, 25].
4.2. Intranasal corticosteroids
In the routine treatment of acute bacterial rhinosinusitis, intranasal corticosteroids (INCSs) 
are recommended as a supplement to antibiotics, especially in patients with allergic rhinitis 
[5, 12, 26]. Intranasal corticosteroids improved the symptoms and had only minor side events, 
consisting of headache, nasal itching, and epistaxis [25].
4.3. Antibiotic treatment
In acute bacterial rhinosinusitis, the most common determined pathogens are S. pneumoniae or 
H. influenzae, so the use of amoxicillin (with or without clavulanate) is commonly recommended 
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for empirical treatment in adult patients [25, 27]. On the other hand, Chow et al. [5] recom-
mends amoxicillin-clavulanate rather than amoxicillin as empirical antimicrobial therapy for 
ABRS in adults. Also, it is recommended to use penicillin or amoxicillin for 7–14 days [10]. 
Macrolides (azithromycin and clarithromycin) are not recommended for initial therapy 
because of high rates of resistance to S. pneumoniae. By the way, trimethoprim-sulfamethoxa-
zole is also not recommended for initial therapy due to high rates of resistance to both S. pneu-
moniae and Haemophilus influenzae. As an alternative treatment to amoxicillin-clavulanate for 
empirical therapy of adult ABRS, doxycycline may be chosen for being highly effective against 
airway pathogens and having superb pharmacokinetic/pharmacodynamics features [5].
Because of the inconstant proportions of resistance among S. pneumoniae, there is no rec-
ommendation for second- and third-generation oral cephalosporin antibiotics in the initial 
monotherapy of ABRS. Combined treatment with a third-generation oral cephalosporin (cef-
podoxime or cefixime) plus clindamycin may be used as a second-line treatment for children 
from geographic regions with high endemic rates of penicillin nonsusceptible Streptococcus 
pneumoniae or for children with non-type I penicillin allergy. İt is strongly recommended 
that the use of doxycycline, levofloxacin, or moxifloxacin may be an alternative treatment for 
initial antimicrobial therapy in adults who are sensitive to penicillin. According to the up-to-
date data, it is not a recommended routine antimicrobial coverage for S. aureus or MRSA for 
the initial treatment of ABRS, even though S. aureus (including methicillin-resistant S. aureus 
[MRSA]) is a possible agent in ABRS, and 5–7 days’ therapy is recommended for uncompli-
cated ABRS in adults [5].
H. influenzae can be highly resistant to amoxicillin and ampicillin [28]. Fluoroquinolones 
remain highly effective against both H. influenzae and S. pneumoniae [29]. Though the role of 
the fluoroquinolones is growing, these drugs are commonly recommended as second-line 
treatment, or as first-line treatment in patients with moderate illness who have had recent 
antimicrobial treatment, or for clinically moderate to severe disease patients [30, 31]. In these 
cases, another treatment option may be using high-dose amoxicillin/clavulanate (4 g/250 mg 
per day). High-dose amoxicillin with clavulanate treatment (2 g orally twice daily or 90 mg/
kg/d orally twice daily) is recommended for adult patients with ABRS who have high risk 
of being infected with an amoxicillin-resistant organism. High-dose amoxicillin/clavulanate 
(4 g/250 mg per day) is recommended for severe infection, findings such as evidence of tem-
perature of 39°C [102°F] or higher and trend of suppurative complications, age over 65 years, 
necessity of hospitalization, antibiotic usage within the last month, immunocompromisation 
and living in geographic regions with high endemic rates (>10%) of invasive PNS S pneu-
moniae. Alternative treatment choice of acute rhinosinusitis comprises of cephalosporins. 
Third-generation cephalosporins, such as cefdinir or ceftriaxone, are enough effective against 
H. influenzae but have much lower effectiveness against S. pneumoniae [27].
4.3.1. Penicillin-allergic patients
Though resistance rates of macrolide antibiotics to H. influenzae and S. pneumoniae are rising 
throughout the world, as first-line agents in patients with β-lactam allergies, they are still pre-
ferred [31]. For these patients, either a fluoroquinolone (levofloxacin or moxifloxacin) or doxy-
cycline is recommended as another agent for initial antimicrobial treatment. For patients who 
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do not have penicillin allergy, fluoroquinolones are not considered as the first-line treatment of 
ABRS, because results are similar to amoxicillin-clavulanate, and side effects are seen higher [27].
4.4. Additional treatments
Clinicians may recommend analgesics, nasal saline, and/or topical intranasal steroids, for 
symptomatic relief of ABRS. Nonsteroidal anti-inflammatory agents or acetaminophen are 
generally adequate for facial pain related to ABRS [25].
4.4.1. Decongestants
4.4.1.1. Topical decongestants
There are no recommendation about topical and oral decongestants as combined therapy. 
Decongestants may offer short-term relief for nasal congestion. Xylometazoline or oxymetazo-
line is the frequently existing topical decongestants. They can be found in the form of drops 
or spray and act by contracting the sinusoids in the nasal tissues. After applying these agents 
intranasally, within 10 minutes, local vasoconstriction occurs. Their effects last up to 12 hours. 
Decreased nasal mucosal blood flow and mucosal clearance may cause this long effect: the 
topical nasal decongestants. Topical nasal decongestants have important side effects such 
as nasal mucosal irritation, dryness, or ulceration. Long-term use (>10 days) of topical nasal 
decongestants may cause tachyphylaxis and rhinitis medicamentosa (rebound swelling of the 
nasal mucosa). Therefore, the use of topical nasal decongestants must be limited to 10 days [5].
4.4.1.2. Oral decongestants
Phenylephrine, pseudoephedrine, and ephedrine are frequently used as oral decongestants. 
As they offer rapid relief on a short term, they are preferred commonly. When compared 
to topical nasal decongestants, oral decongestants have a lower effect on the nasal obstruc-
tion. Because they have no effect of rebound phenomenon, they may be preferred for a long 
term. After oral intake, nasal decongestion starts within 30 minutes and continues for up to 
6 hours. Phenylephrine is the least effective agent among the oral decongestants. There are 
some side effects related to the oral decongestants such as nervousness, drowsiness, agitation, 
and arrhythmias. There are some risks that should be avoided to use oral decongestants in 
combinations with alcohol or some medications such as sedatives and monoamine oxidase 
inhibitors. For patients with stable hypertension, commonly, there is no noteworthy rise in 
blood pressure. However, careful use is recommended in patients with prostatic hypertro-
phy, glaucoma, or ischemic heart disease [27].
4.4.2. Topical anticholinergics
Topical intranasal anticholinergics, such as ipratropium bromide, are mainly preferred to stop 
symptom of rhinorrhea. On nasal congestion, sneezing and itching has no significant effect. 
Nasal irritation, burning, and dryness are the most common adverse effects followed by a 
headache, dry mouth and stuffy nose, etc. On mucociliary clearance, nasal mucosal alteration, 
and olfaction, they have no effect with long-term usage [25].




For management of acute rhinosinusitis, no clinical trials recommend the use of antihista-
mines. First-generation antihistamines have the anticholinergic effects, and thus, mucociliary 
clearance may be impaired. On the other hand, second-generation antihistamines have no 
anticholinergic effect and are not recommended for acute rhinosinusitis [25].
4.4.4. Mucolytics
As a mucolytic agent, guaiphenesin is a frequently used for mucolysis. It is commonly pre-
ferred together with a decongestant drug. While it is used to thin the nasal secretions and 
increase drainage, trials evaluate the effects of placebo and guaiphenesin on ciliary beat fre-
quency and nasal mucociliary clearance, and could not reveal any assessable impact [25].
4.4.5. Oral corticosteroids
When oral corticosteroid steroids are used as monotherapy for ABRS, there is no recommen-
dation to use of systemic steroids for ABRS and they have no advantage over placebo. Among 
their adverse events, in mild condition, gastrointestinal complaints, nausea, and vomiting 
may also be seen. But the effects of these agents must take into account on the systems of 
glucose metabolism, bone turnover, and cardiovascular circulation [25].
5. Medical management of adult chronic rhinosinusitis without 
nasal polyp (CRSsNP)
5.1. Saline treatment
Nasal saline irrigations have beneficial effects and are accepted treatment modality as strong 
recommendation for chronic rhinosinusitis. Among the advantageous effects of saline are 
healing of symptoms and improving quality of life, increase in mucous clearance, improved 
ciliary activity, interruption and elimination of inflammatory mediators, biofilms and anti-
gens, and protection of the sinonasal mucosa [25]. Nasal saline treatment has beneficial safety 
profile, no risk of systemic absorption, and well patient tolerance make it a potent long-term 
topical nasal therapy approach. Irrigation solutions may be either isotonic or hypertonic 
saline. High-volume (>200 mL) nasal saline irrigations in addition to other medical treatments 
is strongly recommended for CRS. Hypertonic nasal saline irrigations notably enhanced 
CRS-specific quality of life, symptom scores, and diminished drug usage. For establishing the 
hygiene, microwave decontamination of the irrigation bottles may be considered as a useful 
disinfecting method. It has been established that saline irrigation is superior to saline spray in 
throwing out secretions and enhancing the quality of life [23, 25].
5.2. Intranasal corticosteroids
It has been shown that the patients with CRSsNP benefited significantly from topical nasal 
steroids. The direct transmission of INCS to the sinuses has a greater impact. Patients with 
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previous sinus surgery have a favorable impact of INCS in comparison with nonsurgical 
patients. INCS have only slight side effects. Modern INCS have no additional clinical effec-
tiveness than the first-generation INCS [23, 32].
5.2.1. Standard delivery (sprays)
The standard measured dose of INCS should be used in the treatment of CRSsNP. There 
is a significant improvement in the endoscopic and symptom scores. Dominance of benefit 
outweighs harm. Aggregated degree of evidence is A. Epistaxis and headache may be seen as 
side effects [23].
5.2.2. Nonstandard delivery (sprays)
Penetration of topical nasal sprays behind the nasal cavities into the paranasal sinuses, espe-
cially in preoperative patients, is expected to be limited. This situation caused a need to use of 
new delivery devices to offer improving corticosteroid deposition in the sinus tissues and for 
possible clinic healing. There are four prominent nonstandard delivery methods: (i) intrana-
sal irrigation, (ii) maxillary antrostomy sinusotomy tubes (MAST), (iii) mucosal atomization 
devices (MAD), (iv) YAMIK sinus catheter. As a consequence, intranasal corticosteroid irriga-
tions are the option in CRSsNP. They may be mostly beneficial for postoperative patients. 
The utilization of MAST or MAD is an option. Use of the YAMIK device is not recommended 
based on up-to-date data [23].
5.3. Oral corticosteroids
There is no clear evidence on the benefits of oral corticosteroids in CRSsNP. Oral steroid 
usage in CRSsNP is optional, due to inadequate strong evidence. Oral steroid use in periop-
erative period with CRSsNP is not recommended. The risks of oral steroids are uncommon, 
but significant side effects should be taken into consideration [10, 23, 33].
5.4. Antibiotics
5.4.1. Oral antibiotics
Sabino et al. [34] stated that 14 days of amoxicillin-clavulanate usage did not change any 
clinical course of acute exacerbations of chronic rhinosinusitis (AECRS) compared to placebo. 
Interestingly, combination of an oral antibiotic with a topical intranasal steroid spray may 
not offer further benefits for managing AECRS. When intranasal corticosteroids and saline 
irrigations have failed to reduce symptoms, long-term antibiotic treatment should be con-
sidered. Macrolide antibiotics have been used in the majority of trials. These antibiotics have 
revealed a response proportion of 60–80%. Roxithromycin has acceptable effects in patients 
without polyp. In a placebo-controlled azithromycin study, [35] suggests that the population 
with high serum IgE are less likely to respond to macrolide treatment. Long-term treatment 
with doxycycline or trimethoprim-sulfamethoxazole could reveal hopeful options. Level of 
evidence for macrolides in patients with CRSsNP is Ib, and strength of recommendation C, 
but in CRSsNP patients with normal IgE, the recommendation level is A [10].
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5.4.2. Oral out of macrolide antibiotics for <3 weeks
When considering the use of antibiotic treatment less than 3 weeks in the management of 
CRS, current data are related to the treatment of AECRS. In addition, there is a shortage of 
suitable prospective trial at present. Because there is no sufficient clinical study and data, the 
ability to make recommendations regarding the use of nonmacrolide antibiotic for less than 
3 weeks in CRSsNP is not applicable [10].
5.4.3. Oral out of macrolide antibiotics for >3 weeks
Although there are significant data on the role of long-term treatment with macrolide 
antibiotics for CRSsNP, there are little data in the literature concerning similar manage-
ment with nonmacrolide agents. Dubin et al. [36] conducted an observational study with 
long-term oral antibiotics in patients with CRSsNP. Thirty five patients with CT scan and 
culture-approved CRSsNP were prescribed antibiotics for 6 weeks. At the end of the study, 
there was no considerable improvement between third and sixth weeks and only 38% of 
the patients reported improvement in CT scan scores. For the treatment of CRSsNP, the 
recommendation of nonmacrolide oral antibiotics for longer than 3 weeks has inadequate 
evidence. So, there is no applicable degree of evidence for the use of oral nonmacrolide 
antibiotics in CRSsNP [23].
5.4.4. Macrolide antibiotics
Macrolide antibiotics have both anti-inflammatory and antimicrobial functions, and for this 
reason, they may be considered to be effective in the treatment of CRS. Previous studies 
on lower respiratory diseases have led to be used macrolide antibiotics in the treatment of 
CRS. In those studies, erythromycin had been used in panbronchiolitis to improve clinical 
symptoms. Aggregated grade of evidence of these therapeutic agents is B. They offer, espe-
cially for patients without elevated IgE, a decline in endoscopy scores and some symptoms 
in patients with CRSsNP. Their effects are comparable to INCS. The effect of the agents may 
not sustain for long term after termination of treatment. They have important risks of drug 
interactions, in frequent mild undesirable events, and severe cardiovascular complications. 
Their benefits seem to outweigh harms. The convenient drug, dosage, and length of therapy 
are not recognized. Macrolides have an optional effect for patients with CRSsNP and were 
judged for the evidence of moderate quality [37].
5.4.5. Intravenous antibiotics
Intravenous antibiotics have a weak evidence in the treatment of CRSsNP. Their aggregated 
grade of evidence is C. There has been possible healing with patient-reported symptoms in 
case-controlled and cohort trials. Among their side effects, bleeding, deep vein thrombosis, 
drug adverse events, elevated liver enzymes, neutropenia, rash, thrombophlebitis, and sepsis 
may be determined. Their cost is high. The harm during the use of these agents outweighs the 
benefits. There is no recommendation for the use of intravenous antibiotics and should not be 
prescribed routinely in CRSsNP [23].
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5.4.6. Topical antibiotics
The aim of topical antibiotic treatment for CRS is to transport high amounts of antibiotics into 
the sinonasal tissues, hence enhancing efficiency, diminishing systemic absorption and related 
side effects. It has been demonstrated that endoscopic sinus surgery increases the penetration 
of topical antibiotic agents from 2 to more than 95%. There is an aggregated grade of evidence 
of B for this management strategy, but randomized controlled trials have been unsuccessful 
to demonstrate any benefit from the application of topical antibiotic agents. Among their side 
effects, epistaxis, irritation, and nasal congestion may be seen. There is no recommendation 
regarding the topical antibiotic treatment in the management of CRSsNP at present [10].
5.5. Antifungal treatment in the management of adult chronic rhinosinusitis 
without nasal polyp (CRSsNP)
5.5.1. Topical antifungals
Physicians should avoid prescribing any topical antifungal therapy for routine patients with 
CRSsNP due to the systemic review of randomized controlled trials. Also, clinicians must 
avoid cost of ineffective therapy, unnecessary side effects, and shift of sinonasal flora [10].
5.5.2. Oral antifungals
For a significant subgroup of patients, fungi are considered as a causative agent of CRS with 
eosinophilic inflammation. Hence, it has been thought that antifungals have a possible effect 
in this subgroup of CRS patients. So, in the standard management of CRSsNP, there has been 
no confirmation about the use of oral antifungal treatment and aggregated grade of evidence 
is not applicable [10].
5.6. Combination treatment with nasal irrigation treatment in the management of 
adult chronic rhinosinusitis without nasal polyp (CRSsNP)
The antimicrobial effects of the sodium hypochlorite (NaOCl), particularly against S. aureus 
and P. aeruginosa, have been well established. Topical nasal irrigation with 0.05% NaOCl in 
saline solution has been found to be more effective than saline alone after 3 months usage 
[10, 38]. For nasal irrigation, xylitol in water is a well-tolerated substance. Xylitol irrigations 
lead to a further healing in chronic rhinosinusitis symptoms compared to saline irrigation 
[10]. It is considered that biofilms have the pathophysiological role in CRS. Surfactants have 
reductive effects on water surface tension and may facilitate dissolving of the biofilms. The 
use of sodium hypochlorite or xylitol nasal irrigations is supported by up-to-date with grade 
of recommendations B, but baby shampoo irrigations are not supported [10].
5.7. Proton pump inhibitors
There is no satisfactory evidence of the use for proton pump inhibitor therapy for CRSsNP 
in adults. Hence, there is also no support for the use of proton pump inhibitors, H2-receptor 
antagonists, antacids, or prokinetic therapy for chronic rhinosinusitis [39].
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5.8. Topical alternative therapies
5.8.1. Surfactants
The benefits of surfactants are clearance of thick secretions and interruption of biofilm forma-
tion. Surfactants have the effects of clearance of secretions and blockage of biofilm develop-
ment. Their side effects comprise ciliary dysfunction and nasal irritation. Although they have 
balanced effects regarding benefit and harm and limited clinical information, it is not possible 
to recommend for the use of surfactants in CRSsNP [23].
5.8.2. Manuka honey
Manuka honey and chief component methylglyoxal have in vitro effects against both the 
biofilm and planktonic formations of Pseudomonas aeruginosa and Staphylococcus aureus. But, 
regarding the routine use of Manuka honey in CRSsNP, no clinical study exists. Possible 
respiratory epithelial damage, nasal irritation, and burning may also be seen. As of the lack of 
evidence, it is not possible to recommend to use Manuka honey in CRSsNP [23].
5.8.3. Xylitol
Xylitol is composed of five-carbon sugar and has the property of improving the innate 
immune system. The main effect of xylitol is to increase the activity of natural antimicrobial 
factors in respiratory secretions [23].
6. Medical management of adult chronic rhinosinusitis with nasal 
polyp (CRSwNP)
6.1. Saline (spray and irrigation) treatment
In the management of CRSwNP, saline is strongly recommended as grade A evidence. Both 
isotonic and hypertonic saline irrigations seem to offer similar subjective results and are well 
tolerated. There is a dominance of benefit rather than harm. It is important to use nasal saline 
irrigation in addition to other topical treatment approaches. There is a superiority of higher 
volume (>200 mL) irrigations over low-volume topical nasal sprays [10, 23, 40, 41]. Regarding 
the patients with difficult to treat sphenoid sinus disease, it has been suggested that the irriga-
tion position of nose-to-ceiling head position is more effective than the nose-to-floor position 
in delivering a 120-mL irrigation to the sphenoid sinuses [42].
6.2. Intranasal corticosteroids: standard delivery (drops and sprays)
In the management of CRSwNP, the use of topical corticosteroids have keystone role. 
Intranasal corticosteroids (sprays or drops) are recommended before or after the surgery for 
CRSwNP. The use of INCS as sprays or drops have noteworthy benefits. Its advantages include 
improved symptoms, endoscopic views, size of polyp, quality of life, objective tests of smell, 
airway, and polyp relaps. Headache, epistaxis, and nasal mucosal damage may be seen as side 
effects [23, 40, 41, 43].
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6.3. Intranasal corticosteroids: nonstandard delivery (irrigation and nebulizers)
Nonstandard topical corticosteroid delivery system, especially after sinus surgery, is an 
option in CRSwNP. General benefits are not available to statistically approve therapeutic 
recovery on existing evidence. Although evidence of adrenal suppression has not been seen, 
this cannot be ruled out by nonstandard delivery and dosing regimens. They have off-label 
use and possible minor side effects in comparison with oral corticosteroids [23].
6.4. Oral corticosteroids
The short-term oral corticosteroids usage in treatment of CRSwNP is strongly recommended. 
Both in subjective and objective measurements, this treatment provides a considerable short-
term healing in the patients with CRSwNP. Patients must be prescribed systemic corticosteroids 
in acute aggravations of CRSwNP. The recovery time may take 8–12 weeks with the use of 
INCS. Further gastrointestinal complications may also be seen. There may be temporary adre-
nal inhibition, insomnia, and elevated bone turnover. With long-term management, the entire 
well-known corticosteroid complications may be seen. Corticosteroid agents have significant 
benefits over harm in short-term usage. The use of corticosteroids in long term or frequently is 
not encouraged by the literature and has further risk of damage to the patients [10, 33, 37, 40, 43].
6.5. Antibiotics
6.5.1. Oral out of macrolide antibiotics for <3 weeks
In general, there is no recommendation to prescribe nonmacrolide antibiotics less than 3 weeks 
course for the patients with nonacute clinic conditions of CrSWNP. Oral doxycycline therapy for 
3 weeks decreases the polyp size and postnasal discharge, but this therapy cannot decrease the 
other complaints in patients with CRSwNP compared to the placebo. Because there is no placebo 
in the erdosteine study, it is impractical to establish a benefit. There may have gastrointestinal dis-
comfort and risk of resistance and anaphylaxis. There may be more harm than benefits [10, 23, 40].
6.5.2. Oral out of macrolide antibiotics for >3 weeks
Long-term oral nonmacrolide antibiotics for more than 3 weeks course in the management of 
adult chronic rhinosinusitis with nasal polyp (CRSwNP) is not currently recommended [10, 23].
6.5.3. Macrolide antibiotics
Macrolides may have advantageous effects after endoscopic sinus surgery to reduce polyp 
recurrence and recover symptoms of CRSwNP. Benefits have shown outweigh harm. They 
may have considerable drug interactions. Also, they may cause infrequent but serious cardio-
vascular complications [10, 23].
6.5.4. Topical antibiotics
Topical antibiotic agents have efficiency in just lower stage studies and have unidentified 
systemic absorption and side-effect scale. So, they should be prescribed only if conventional 
management modalities (oral antibiotics, steroid sprays, saline) are unsuccessful [10, 23].





For the treatment of CRSwNP, there is no recommendation for prescribing oral antifungal 
agents. Liver function tests may be deteriorated during systemic usage. Because there is a lack 
of evidence for the use of oral antifungal therapy, there is a greater risk of adverse effects than 
potential advantages. For the usual management of CRSwNP, clinicians should not prescribe 
the oral antifungal drugs [10, 23].
6.6.2. Intranasal antifungals
For the usual CRSwNP treatment, topical antifungal medications should not be utilized. In 
the management of typical CRSWNP, there is no benefit of topical antifungals, but there may 
be some benefits in some CRSwNP subdivisions, such as allergic fungal sinusitis. Because 
they have unconfirmed systemic absorption and side-effect scale, topical antifungal agents 
should only be considered if routine treatment modalities failed [10, 23, 41].
6.7. Anti-LT therapy
For patients with CRSwNP, montelukast may be useful and an option to substitute or supplement 
to INCS. Symptoms can be improved when compared to the INCS and may have limited ben-
efits in addition to the INCS. Montelukast is in association with infrequent neuropsychiatric side 
effects in post-sale records. In addition, there has been also in association with high liver enzymes 
and Zileuton and other medications [23]. On the contrary, anti-leukotriene treatment is not sup-
ported for the patients with CRSwNP and this treatment modality is not recommended [10, 23].
6.8. Aspirin desensitization
This therapy must be considered and recommended in patients with aspirin exacerbated rhi-
nitis disease to impede postoperative nasal polyp renewal. The aggregated grade of evidence 
is B. Benefits include decreased polyp reformation after surgery, decreased CRS symptoms 
in increased QoL and AERD, reduced the need for systemic corticosteroids, and decreased 
number of reoperations. It is necessary to be vigilant for gastrointestinal bleeding. It should 
be noted that this treatment has the potential to increase morbidity in patients with kidney 
disease and blood clotting  problems with the increasing doses. There has been lower than 3% 
gastrointestinal complaints throughout the low-dose treatments. Absolute benefit is present 
rather than harm. Aspirin desensitization is a unique treatment modality for aspirin-sensitive 
patients with CRSwNP [10, 23].
6.9. Immunotherapy
For postoperative period of AFRS patients, this treatment modality offers an option with bal-
anced benefit and harm. There is a limited data and the grade of evidence is C. If a patient rep-
resents enhanced sensitivity to the certain antigens, immunotherapy may be used to diminish 
the inflammatory load [23, 40].
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6.10. Anti-IL 4 and anti-IL13 treatment
An anti-IL-4/13α subunit receptor antibody, dupilumab, has been approved for atopic derma-
titis [44]. Add-on therapy of dupilumab may have a role in nasal symptom relief for patients 
with uncontrolled persistent asthma and comorbid persistent allergic rhinitis [45]. It has 
been observed that for the patient with nasal polyp, addition of subcutaneous dupilumab to 
mometasone furoate nasal spray reduced endoscopic nasal polyp scores after treatment. More 
sophisticated studies are needed to evaluate for longer treatment duration and larger patient 
samples [46].
6.11. Anti-IL5
Reslizumab is an anti-IL5 mAb derived from human tissues and acts diminishing the amount 
of eosinophils both in tissue and blood. Anti-IL5 antibodies may have benefit in the manage-
ment of CRSwNP patients [10].
Mepolizumab, FDA approved for severe eosinophilic asthma, is another anti-IL-5 human 
derived antibody that has been studied in patients with CRS. For the patients with recurrent 
nasal polyposis, who receiving topical corticosteroids and required surgery, mepolizumab 
treatment showed a huge reduction in the need for surgery and a huge improvement in symp-
toms than placebo [44, 47]. Also, there is a continued clinical trial of mepolizumab in the 
patients with CRSwNP refractory to medical and surgical therapy [48].
Benralizumab is another anti-IL5 molecule that could potentially have some benefits for 
inhibiting the IL-5 pathway in CRS [44].
6.12. Anti-IL13
Lebrikizumab did not substantially heal FEV1 in mild-to-moderate asthma patients by 
inhibiting IL-13 pathway. Inhibiting IL-13 in this patient population was not satisfactory to 
improve lung function [49].
Tralokinumab, an agent of anti-IL13, in severe asthma exacerbations, has not been considered 
as a key role for interleukin 13, and it was stated that Tralokinumab is unsuccessful for man-
agement of severe, uncontrolled asthma [50–52].
Anrukinzumab is a humanized anti-IL-13 monoclonal antibody, which acts to block the cyto-
kine and prevent the activation of IL-13Rα1 and IL-13Rα2 [53, 54].
So far, there is no approved anti-IL13 treatment modality for the patients with CRwNP.
6.13. Anti IgE
Omalizumab is a human-derived anti-IgE monoclonal antibody that prevents binding of IgE 
to receptors on mast cells and basophils. Omalizumab has been approved for severe allergic 
asthma [44]. Anti-IgE therapy also reduces nasal polyp score in patients with severe comorbid 
asthma [55].
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6.14. Intranasal triamcinolone acetonide/carboxymethylcellulose foam
For acute exacerbations of postoperative CRSwNP patients, it has been observed that topical 
triamcinolone acetonide/carboxymethylcellulose foam reduced systemic steroid need, is well 
tolerant, and a good treatment option [56].
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